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The precise identification of the form of angiotensin recovered
'from in vitro incubation for plasma renin activity (PRA) determinations
has become increasingly important with chemical means for quantisation
such as radioimmunoassay. The ability to discriminate A I and A II
quantitatively in mixtures of these peptides also provides means for
quantitative assessment of angiotensin converting enzyme activity.
Consequently, measurement of the ratio of A I and A II recovered as the
37 C incubation product in plasma by radioimmunoassay has been used to
examine plasma converting enzyme activity (PCEA).
The antibody capture method was used for the determination of A II
concentrations in plasma from 3 experimentally induced hypertensive
models of male Sprague-Dawley rats. This method provides for the capture
of A II formed by the action of the plasma converting enzyme by use of
an excess of A II antiserum during the 37 C incubation process. Simul
taneous measurements of A I concentrations which demonstrates PRA's were
also determined. Whenever an increase or decrease in PRA was observed,
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similar activities were demonstrated by the plasma converting enzyme.
As blood pressure increased in one model of hypertensive rats that
had the left renal artery constricted with simultaneous removal of the
right kidney, an increase in both PRA and PCEA was observed. Increases
in these enzymatic activities, apparently caused by renal artery con
striction, are assumed to be due to a negative sodium balance. Sodium
depletion of this type is believed to be due to an excessive loss of so
dium from the circulating blood by the kidney tubules. These physiologic
phenomena apparently result in increased renal enzymatic activities. In
contrast to these findings, similar PRA and PCEA activities were observed
in one kidney nephrectomized control rats at 10 days. However, decreases
in PRA and PCEA at 20 and 30 days indicate that some animals with only
one functional kidney presumably have the ability to auto-regulate, and
thereby maintain homeostasis. These results indicate an active physio
logical role of the converting enzyme in the maintenance of blood
pressure. Increases or decreases in PCEA result in either increased or
decreased concentrations of A II, the vasoconstrictor hormone of the
renin-angiotensin system.
The same enzymatic activities were significantly reduced in a group
of rats given 1.5% saline to drink for 30 days. The results were assumed
to be caused by suppression of the renin-angiotensin system due to chronic
salt ingestion.
In another group of rats that were administered injections (ip) of
5-hydroxytryptophan simultaneously with injections (sc) of estradiol
benzoate, PRA and PCEA decreased by 100% and 131.2%, respectively, from
that of the control animals. The serotonin hormone precursor, 5-HTP,
apparently has a nephrotoxic effect on the kidney, thereby causing
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decreased enzymatic activities.
The ability of the radioimmunoassay procedures used to detect very
low concentrations of A I and All was determined prior to the assay on
experimental plasma samples. Plasma from 36 hr 2-kidney nephrectomized
rats and plasma from a group of SHR's was assayed to make these deter
minations. PRA and PCEA were significantly decreased in plasma from the
2-kidney nephrectomized rats due to the removal of the source of the
renal enzyme (renin). PRA was 60 times greater in the SHR's plasma than
that observed in the 2-kidney nephrectomized rats. In the meantime PCEA
was increased by approximately 700%. While these results show the va
lidity and effectiveness of the radioimmunoassay, they simultaneously
implicate the converting enzyme (CE) as an important factor in
regulating the levels of A II in plasma which subsequently regulate
blood pressure. These results further imply that it is important to
measure converting enzyme activity (CEA) under conditions in which the
renin-angiotensin system is suspected of playing a role. This is evident
from these results since regulation of CEA might not be reflected in
measured PRA. Under these conditions the importance of CEA is a better
index of hypertension of a renal orgin than renin, because the action of
the CE is the last step in the enzymatic reactions of the renin-angioten
sin system, with the subsequent liberation of A II.
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The renin-angiotensin system has been under investigation for many
years. It has been established that the renal enzyme, renin, acts on
the renin substrate, antiogensinogen. This reaction results in the
formation of the decapeptide angiotensin I (A I), generally believed to
be biologically inactive. To achieve biological activity, A I must be
cleaved by a converting enzyme in the circulation. This reaction pro
duces the biologically active octapeptide angiotensin II (A II). Based
on these observations, the converting enzyme is the apparent cornerstone
in the renin-angiotensin system, yet little is known about its physio
logical activity.
The discovery and description of the A I converting enzyme from
plasma may be dated from the early work of Skeggs et al. (1954,1956) and
that of Helmer (1957). Except for the work of these investigators, and
especially Ng and Vane (1968), who indicated that most of the angio
tensin conversion occurs in the lungs, little is known about the convert
ing enzyme. Early studies with this enzyme implied that the primary site
whereby A I was converted to the active form, A II, was localized in
plasma. It was soon realized however, that the rate of conversion by the
plasma enzyme was not sufficient to account for the rapid rise in blood
pressure following intravenous injection. The tissue responsible for
the primary conversion remained unknown until the work of Ng and Vane
(1968). They found that the primary site of conversion appeared to be
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the lungs. Support for this site was also reported by Huggins and
Thampi (1968) who observed that under in vitro conditions, lungs con
tained a relatively high content of converting enzyme. Cushman and
Cheung (1969) reported studies on the purification of A I converting
enzyme from dog lung homogenates and described some of its kinetic pro
perties. Oparil et al. (1970) have shown a rapid pulmonary conversion
of tritium-labeled A I under in vivo conditions.
The first method for measuring plasma converting enzyme activity
(PCEA) was reported by Skeggs et al. (1956) and was based on an eight-
tube countercurrent distribution procedure for the separation of A I
from A II. Helmer (1955) used a spirally cut strip of rabbit aorta
which responded to A II but not to A I, in order to measure the capacity
of human plasma to form A II. More recently, A I labeled at the C-
terminal amino acid was used by Huggins and Thampi (1968) for the mea
surement of A I converting enzyme activity. Boucher et al. (1970) used
a cation exchange adsorption technique for the same purpose. The pro
cedure consisted of the elution of A I and II adsorbed on one column of
50W-X8 (NH4+) Dowex resin into a second column. A I was adsorbed on the
second column of 50W-X8 Dowex resin, while A II went through and was
collected in a si 1 iconized flask and later lyophilized. The amount of
A II formed by the action of the converting enzyme on the A II substrate
after a 20 min incubation period at 47 C was measured by biological assay
using nephrectomized rats. Reproducibility was within a range of 15%.
All these methods essentially measure A II once it has been separated
from A I, or they measure A II in the presence of A I on the assumption
that the radioimmunoassays are highly specific for both angiotensins.
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The development of radioimmunoassay techniques, with their
application to low molecular weight peptides, has permitted the measure
ment of A I and A II (Waite, 1972b). In general, it appears that there
has been little difficulty in raising antisera of high specificity and
avidity to both A I and A II. These antibodies have been raised against
immunogens prepared in a variety of ways. The immunogen complexes have
consisted of angiotensin with porcine gamma globulin, rat serum albumin
(Goodfriend et al., 1964), poly-L-lysine (Haber et al., 1965) and micro-
particles of carbon (Peart, 1969). These various immunogens have been
employed in different animals, and with varied immunization schedules.
The animal most often used has been the rabbit. With the presence of
tyrosine in the compound, the preparation of labeled A I with 125I or
IJII of high specific activity has been achieved with comparative ease
using the chloramine-T method of Hunter and Greenwood (1962).
The development of suitable extraction procedures has in recent
years permitted the measurement of the concentration of A II in blood or
plasma. Until recently, however, the radioimmunoassay of A I has been
limited to the measurement of plasma renin concentration. More recently,
suitable techniques for the extraction of A I have been developed and
the circulating levels of A I have been measured. Using the assay tech
nique of Brown et al. (1966) to measure plasma renin concentration, and
the technique of Dusterdieck and McElwee (1971) to measure plasma A II,
Waite (1972a) found a significant relationship between plasma renin and
plasma A II concentrations and demonstrated that there is a strong
positive correlation between A I and A II.
Current enzyme assays are most often performed by allowing the
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enzyme to act on its substrate under standard conditions with subse
quent analysis of the product. This principle is also used when the
product is measured by radioimmunoassay; the antibody against the product
is added after the enzymatic incubation has taken place. Poulsen (1971)
introduced a simplified method for the radioimmunoassay of enzyme systems.
His procedure introduced a new application for radioimmunoassay. The
principle consists of the presence of an excess of radioimmunoassay anti
body at the start of the enzymatic incubation. The antibodies can cap
ture an intermediate product such as angiotensin formed with time, and
thereby, protect it against enzymatic degradation. Subsequent to the
enzymatic reaction, the incubation mixture is diluted and labeled angio
tensin is added simultaneously. Finally, free angiotensin is removed with
charcoal, and counting of the antibody-bound angiotensin gives the amount
of captured angiotensin with an accuracy of ±0.04. The method is simple
and the whole procedure, except for counting, is performed in the same
tube.
This assay, if used for A II, can be used with an analogous assay
for A I in order to ascertain the activities of the converting enzyme.
At present it is possible to obtain highly specific affinity antibodies
against both hormones (A I and A II) with less than 5% cross-reactivity.
Therefore, the major purpose of this investigation was to study the ac
tivity of the converting enzyme of the renin-angiotensin system during
the development and maintenance of hypertension in one model of spon
taneously hypertensive rats (SHR) and three models of experimentally
induced hypertensive rats. The hypertensive models are as follows:
1) one kidney Goldblatts, 2) salt-induced, 3) 5-Hydroxy-DL-tryptophan
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induced, and 4) SHR's. The antibody capture technique for A II
proposed by Poulsen (1971) was used to elucidate these phenomena, with
subsequent radioimmunoassay analysis of the A I and A II hormones in
the plasma of each hypertensive model.
CHAPTER II
REVIEW OF LITERATURE
Various aspects of the renin-angiotensin system have been studied
for many years. The first observations were made by Tigerstedt and
Bergman in 1898, when they extracted renin from rabbit kidneys and
showed that it would raise the blood pressure in dogs and that its
activity could be destroyed by boiling. Little interest was taken in
these observations until 1934 when Goldblatt and his colleagues showed
that the application of a clip to one renal artery would raise the blood
pressure in the experimental animal (Goldglatt et al., 1934). Conse
quently, for about 36 years after its discovery renin was only a curio
sity and a matter of dispute because no particular attention was paid to
the enzyme's possible significance since the idea of primary (non-renal)
hypertension was dominant. According to Berman and Vertes (1973) it is
no exaggeration to call Goldblatt's experiment one of the most important
in modern science for it not only reestablished the forgotten enzyme,
but also led to some of the modern concepts of hypertensive disorders.
After Goldblatt's experiment many investigators began to look again
at the possibility of release of pressor substances from such a kidney,
and renin was rediscovered in kidney extracts (Pickering and Prinzmetal,
1938). The subsequent work of Page and Helmer (1940) and Braun-Menedez
et al, (1939,1940) led to the discovery that renin was an enzyme which
acted on a substrate in the plasma to produce pressor activity called,
initially, angiotonin by Page and his associates and hypertensin by
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Braun-Menendez and his coworkers. The name of this pressor substance was
later changed by agreement and called angiotensin (Page, 1975). It has
subsequently been shown that this activity is due to the production of
a decapeptide which is readily changed to an octapeptide in the circulation
(Skeggs et al., 1955,1956; Elliott and Peart, 1956,1957).
Early efforts to isolate and characterize angiotensin were hampered
by the presence of angiotensinase (peptidase) in renin and renin substrate
preparations. The problem was overcome by using techniques which destroyed
peptidase activity by acidification (Poulsen, 1969a) and by charcoal ad
sorption of angiotensin as soon as it was formed, thus rendering it
inaccessible to peptidase activity or by preliminary purification to ex
clude angiotensinase from the system (Peart, 1955,1956; Boyd et al.,
1969). First, horse angiotensin (Skeggs et al., 1955), then bovine
(Elliott and Peart, 1956,1957), hog (Bumpus et al., 1957) and human
(Arakawa et al., 1967) angiotensin I (A I) were isolated. By the use of
several amino acid analysis techniques, both Skeggs et al. (1955) and
Elliott and Peart (1956,1957) were able to concurrently identify the amino
acid sequence in A I; the sequence was Asp.Arg.Val.Try.lie.His.Pro.Phe.
His.Leu, respectively. The first pure A I was obtained by Skeggs et al.
(1954) from the incubation of pig renin with renin substrate obtained
from horse plasma. The material was shown to be a decapeptide, with
nine different amino acids and with an isoelectric point of 7.7. Its
amino acid composition was substantiated by Lentz et al. (1956) when
they demonstrated the amino acid composition of hypertensin II and
showed its biochemical relationship to hypertensin I. Confirmation of
the sequence has since been made through synthesis of the peptide by
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Bumpus et al. (1957) and Rittel et al. (1957) during the period when the
Merrifield solid-phase method of synthesis was unknown (Page, 1975).
Human, horse and hog A I are identical in their amino acid sequence, but
bovine A I differs in that valine replaces isoleucine in the five-carbon
position.
Skeggs et al. (1954) discovered two forms of angiotensin that could
be separated by a 50 tube countercurrent distribution method. One of
the products (A I) was the decapeptide produced by the action of renin on
the renin substrate (angiotensinogen). The second product (A II) was the
octapeptide formed after the removal of the terminal histidyl-leucine
from A I. In the absence of plasma, A I exhibited no significant vaso
constrictor properties, either on isolated rabbit aortic strip (Helmer,
1957) or the perfused isolated rat kidney (Ng and Vane, 1968) whereas,
A II was highly active. Such observations led to further awareness of
an enzyme in plasma that converts the decapeptide to an octapeptide.
The work of Page and Helmer (1940) and of Braun-Menendez and his
colleagues (1940) demonstrated that renin was not, by itself, a pressor
agent and that some factor in plasma was necessary to produce its pressor
activity. Both groups, therefore, suspected the existence of an activa
tor, co-factor, or a substrate in plasma. Work by Plent et al. (1943)
demonstrated that this co-factor was the renin substrate and that it
could be characterized as a protein contained largely in the a2-globulin
fraction of plasma. Subsequently, in a series of important experiments,
Skeggs et al. (1964) provided considerable information on the nature of
renin substrate. This group was able to degrade horse renin substrate
by treatment with trypsin and thereby obtain a 14-amino acid residue
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polypeptide. This tetradecapeptide yielded A I upon incubation with
renin. The first 10 amino acids from the N-terminal group were identi
cal with those found in A I. The structure of the tetradecapeptide
was later confirmed by synthesis and it was established that renin
acts on this substrate at the leucyl-leucyl bond to liberate A I and
a tetrapeptide. The organ source of the circulating renin substrate
(angiotensinogen) has not been established unequivocally but a hepatic
source seems likely. Observations by Page et al. (1941) and Leloir
et al. (1942) indicate that hepatectomy reduces renin substrate. Stu
dies by Drury et al. (1951) indicate that hepatectomy also eliminates
responses to injected renin. In support of these studies are other ob
servations indicating that plasma renin substrate may be very low or at
times even undetectable in patients with liver disease (Ayers, 1967).
Renin substrate has not been identified in extracts of liver, spleen,
lungs or heart (Munoz et al., 1940). However, more subsequent studies
indicate that hepatic tissue cultures can generate renin substrate.
The current state of knowledge of the components of the renin-
angiotensin system wherein renin, after its release into the circulation,
acts on its substrate (angiotensinogen) to produce the decapeptide (A I),
and its subsequent conversion by the converting enzyme to the biologically
active octapeptide (A II), is due to the work of Bumpus et al. (1961),
Peart (1965) and Brown et al. (1966). According to Peart (1969) it is
apparent that the amount of substrate present in the system affects the
rate of reaction, and the rate of conversion of deca- to octapeptide will
limit the amount of biologically active end product appearing in
circulation. The work of Ng and Vane (1968) demonstrated that large
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amounts of A I are converted to A II in transit during a single passage
through the lungs rather than in the circulation itself. While in
circulation A II is subject not only to the degradative action of the
various angiotensinases present in blood, but also to clearance in
transit through tissues. It is therefore likely that most of the meta
bolic clearance is carried out within the tissues rather than in the
blood.
According to Vane (1969) renin has a long half-life in the circula
tion (15 min) in comparison with a single circulation time of 15 to 30
sec. It therefore circulates again and again, and the gradual decrease
in its concentration is due to liver inactivation. By its action on
angiotensinogen, renin generates A I especially on the venous side of
circulation and it is relatively stable. However, A I is subsequently con
verted to the more active A II as it passes through the lungs. A I
formed on the arterial side remains unconverted and most of it (50 to
70%) disappears in the peripheral vascular beds without being converted
to A II (Ng and Vane, 1968). The 30 to 50% of A I which survives pas
sage through peripheral vascular beds mixes with that which is converted
to A II in the lungs. It is not known how quickly the angiotensinases
in the blood degrade A I but any such degradation is probably slow.
A II formed in the lungs is stable in blood (half-life, 3 min)
compared with its disappearance (50 - 60%) in a single passage through
peripheral vascular beds. That which passes through the peripheral
vascular beds recirculates, however, there is no removal of A II in
pulmonary circulation (Hodge et al., 1967).
The renin-angiotensin system is evidently an enzyme system in which
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renin is the enzyme and angiotensin the product of the enzymatic
reactions (Skeggs et al., 1959). A II is responsible for all the
known effects of the system. It is the most effective pressor
substance and influences the salt and water balance through its
effect on the kidneys and adrenals. The interest in the system is
due to the unsolved question whether or not the renin-angiotensin
system is active in the production of the various types of hyperten
sion (Poulsen, 1970).
Renin is a proteolytic enzyme that is synthesized, stored and
secreted mainly by the kidney. Oparil and Haber (1974) reported
that renin-like enzymes have been extracted from a variety of organs,
including the uterus, placenta, fetal membranes, amniotic fluid, brain
adrenal glands, and the submixillary glands of the white mouse. Extra-
renal sources have been used to explain the occasional finding of renin
activity in the blood of anephric subjects (Capelli et al., 1968), but
there is yet no evidence that these extrarenal sources have any physio
logic role in blood pressure regulation or that the enzymes are identical
with renal renin.
Although the enzyme is found in high concentrations in various or
gans, renin is concentrated mailny in the epithelial cells of the juxta-
glomerular apparatus in the kidney (Fraup, 1968). The only known place
in which all of the components of the renin-angiotensin system are found
together is in plasma. Poulsen (1970) reported that the half-life of
renin is 24 - 90 hr whereas that of the converting enzyme is in the
range of 2 - 10 min, and the peptide enzymes (angiotensinases) approxi
mately 5 min. Based on these data renin is the rate-limiting enzyme.
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In spite of this, the concentration in plasma of the biologically
active octapeptide A II, is not solely determined by the concentration
of renin.
Observation of the actions of the angiotensins led to the study
of the enzymes involved in the metabolism of the liberated peptides,
including the A I converting enzyme. The A I converting enzyme was
discovered by Skeggs and his associates in the mid 1950's when they
noticed that horse plasma contains an enzyme that converts A I to
A II (Skeggs et al., 1954,1956; Lentz et al., 1956). They reported
that renin releases the decapeptide (A I) from angiotensinogen and that
this decapeptide is in turn converted to the octapeptide (A II) when
the converting enzyme cleaves a histdylleucine dipeptide from the C-
terminal end of A I. The enzyme requires chloride ions and is inhibited
by ethylenediamine tetraacetic acid (EDTA) or other chelating agents
such as dimercaprol (BAL) or 8-hydroxyquinoline. These observations
strongly suggest that the enzyme is a metalloenzyme. Around the same
time Helmer (1955) also observed the existence of a factor in plasma
that activated angiotensin preparations.
After these discoveries, the matter lay dormant for a long time,
because A I was not available in pure or synthetic form in substantial
quantities. The issue of conversion was kept alive, however, because of
the difference between the effects of A I and A II on isolated smooth
muscle preparations. It was observed that A I must be converted to A II
before it becomes active in most biological systems in vitro (Skeggs
et al., 1956). By means of a spirally cut strip of rabbit thoracic
aorta Helmer (1957) demonstrated that angiotensin exists in two forms.
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One form, A II, causes a contraction of the strip. The other, A I, is
inactive. They are equally pressor when injected intravenously in ani
mals. An enzyme in plasma converts the inactive form to the active form.
The identical pressor activity can be explained by the excess of the con
verting enzyme in the plasma of the intact animal which rapidly converts
A I to A II. Bumpus et al. (1961) used the isolated rat uterus for the
same purpose. Anderson (1967) reported a similar bioassay technique.
Several chromatographic procedures for separating A I and II have been
described. A I labeled at the C-terminal amino acid was used by Huggins
and Thampi (1968) for the measurement of A I converting enzyme in rat
plasma, heart, brain, liver, diaphragm, kidney, lung, aorta and uterus.
Helmer (1957) also reported that some patients with hypertension have
a greater content of the converting enzyme in their plasma than is found
in normotensive subjects. It was suggested that in addition to the con
verting enzyme, other factors in plasma may enhance the ability of angio-
tensin (i.e., catecholamines, prostaglandins, norepinephrine, etc.) to
induce constriction of tissues in bioassays. These factors may sensitize
the mechanisms in the muscle tissue which set up the process of contraction.
Erdos (1975) reported in a review article that the need for such
conversion in vivo is not that noticeable because the two peptides have
similar effects on systematic blood pressure after intravenous injection
due to the rapid conversion of A I in the body. It has been difficult to
measure the conversion of A I to A II by bioassay, because tissues which
contain the converting enzyme also inactivate the released peptide.
Estimation of conversion in vitro gave only semiquantitative data
(Bumpus et al., 1961) until radioactive substrates became available.
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The measurement of renin activity, concentration and substrate has
been widely performed by bioassay of the A I generated during incubation
of plasma samples in vitro (Boucher et al., 1964; Pickens et al., 1965;
Helmer and Judson, 1963). Recent studies in human beings (Skinner et al.,
1969) and rats (Menard et al., 1970) have demonstrated that measurements
of all three parameters concerned with renin activity in vivo—plasma
renin activity (PRA), plasma renin concentration (PRC), and plasma renin
substrate (PRS)—are necessary for complete evaluation of changes in
the renin-angiotensin system. In small animals such as the rat, simul
taneous measurement of these parameters has not been possible due to
the volume of plasma required for use with the bioassay (Menard and Catt,
1972).
Radioimmunoassays for A I have been applied to the measurement of
PRA in man, giving results which appear to correlate well with those
obtained by bioassay (Boyd et al., 1969; Haber et al., 1969; Waite et al.,
1972a). As radioimmunoassay of A I is considerably more sensitive than
bioassay methods, Menard and Catt (1972) applied it to the assay of PRA,
PRC, and PRS during studies in the rat, and developed methods which
allow all three measurements to be performed on small blood samples.
These methods are applicable to the assay of renin parameters in the plasma
of other species. They also allow for the simultaneous measurement of
all three parameters in the renin-angiontensin system.
Regardless of the method used in many situations, Boyd et al.
(1967, 1969) concluded that the bioassay methods available for the esti
mation of A II in human plasma did not possess sufficient sensitivity for
this hormone in various physiological and pathological states, therefore,
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they considered the use of radioimmunoassay techniques. A major
difficulty with attempts to apply the radioimmunoassay technique
to A II had been the problem of developing a suitable antibody.
A II was found to be an octapeptide with a small molecular weight of
approximately 1,000 and antigenically weak. Some success had pre
viously been achieved by immunizing with angiotensin which had been
covalently linked to larger carrier molecules (Haber et al., 1965;
Catt et al., 1967). Recently, radioimmunoassays for angiotensin III
(A III), based on such antibodies, have been reported from two separate
laboratories (Vallotton et al., 1967; Catt et al., 1967).
In an effort to achieve maximum avidity and specificity of the
antibody to A II, Boyd et al. (1969) reported success in their attempts
to raise antibodies only against the free angiotensin molecule itself.
These investigators raised antibodies in rabbits by immunizing with
Val -A II amide adsorbed onto micro-particles of carbon. According to
the method of Peart (1955), carbon was used as the adsorbent because of
its high affinity for A II and its ability to protect the molecule
against the action of the plasma angiotensinases. The subsequent use
of such high titre antibodies in the radioimmunoassay of A II in human
circulating plasma has been reported (Boyd et al., 1967, 1969). The
test used in these experiments was able to detect 30 pg amounts of A II
and was not influenced significantly by A I.
Since 1967 other investigators (Vallotton et al., 1967; Catt et al.,
1967; Sundsfjord, 1970; Dusterdieck et al., 1971; McBride et al., 1971)
described radioimmunoassays for A II which detect small amounts of the
peptide, but lengthy extraction and concentration procedures were
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required. Reports by Vallotton et al. (1967) and Goodfriend et al. (1968)
also indicated a lack of agreement between measurements of A II (generated
in vitro by incubation with renin) obtained by the rat pressor assay and
that measured by radioimmunoassay of the same sample.
Gocke et al. (1968) described the range of concentration of A II in
normal human subjects and documented the variations in A II concentrations
with changes in sodium intake. These workers also correlated the varia
tions with renin activity. Their findings were obtained using a simple
rapid radioimmunoassay procedure capable of measuring A II directly from
0.1 ml of human plasma. The validity of the measurement was substantiated
by the ability of the immunoassay to duplicate results obtained by the
pressor bioassay of the A II generated in vitro by incubation with either
endogenous or added renin. In experiments performed by Gocke et al. (1968),
A II was generated by incubation at 37 C with endogenous renin for 24 hr
or with increments of highly purified human renin for 30 min. Excellent
agreement between bioassay and immunoassay determinations was obtained ex
cept when 0.003 M EDTA was present in the renin-generation step. In this
case, less than 1% of the A II found by bioassay was detected by the radio
immunoassay. This was most likely caused by the inhibition of the conver
sion of A I to A II by the presence of EDTA. In most radioimmunoassay pro
cedures reported, the antibody shows very little cross-reaction with the
decapeptide. Thus, the antibody fails to recognize the A I formed. However,
on injection of the sample into the rat for bioassay, A I is rapidly and
quantitatively converted to the pressor substance, A II. When the plasma
was dialyzed to remove the EDTA prior to the incubation step full agreement
between the two assay methods was obtained. This correlation of immunoassay
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and bioassay measurements provided important verification that both methods
measure the same substance and ruled out the possibility that degradation
products or other factors in plasma cross-react with the antibody to any
significant extent.
Sensitive and reproducible bioassays have been used to elucidate much
of what is known of the renin-angiotensin system. Most of the procedures
were based on the ability of A II to cause smooth muscle contraction.
Biologic response was assayed either directly or after an incubation step
in which the renin-substrate reaction was allowed to take place under
standardized conditions, thus generating angiotensin and giving a measure
of renin activity. The biologic response was either contraction of rabbit
aorta (Helmer, 1957) or rat colon (Needleman et al., 1972) or the systematic
pressor effect in an intact nephrectonrized rat (Boucher et al., 1961).
Responses were related to control injections of standard A II. Although
precise and reproducible measurements of plasma renin activity have been
obtained by bioassay in many research laboratories, the wide clinical ap
plication of this approach has been limited by inconsistent standardization
and reproducibility, undue time requirement for sample processing, and
frequently a lack of sensitivity and specificity (Oparil and Haber, 1974).
Radioimmunoassay for A II and A I became possible because highly
purified synthetic peptides for use as antigens became available. By
coupling angiotensin to a macromolecular carrier such as poly-L-lysine
(Haber et al., 1965), a protein (Deodhar, 1960; Goodfriend et al., 1964)
or finely divided charcoal (Boyd and Peart, 1968) an effective immunogen
was created. The hapten-carrier complex gave rise to specific high
affinity antibodies. Studies with peptide analogues and degradation pro
ducts of A I and II showed that there was less than 5% cross-reactivity
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between most anti- A I and anti- A II antibodies (Haber et al., 1965).
Furthermore, except for the carboxyl hepta-peptides and hexa-peptides,
the degradation products of A II were nonreactive with most anti-
angiotensin antibodies (Dietrich, 1967). Vallotton (1971) reported
that since the structural requirements for biologic and immunologic ac
tivity in the A II molecule are similar, fragments of A II do not impair
to any great degree the usefulness of the A II radioimmunoassay in circu
lating plasma.
Labeled peptides of high specific activity for the radioimmunoassay
procedures were obtained with I by the chloramine-T technique of
Hunter and Greenwood (1962). A modification of the procedures made it
possible for the production of a monoiodinated peptide by Nielsen et al.
(1971) that is stable for many months. Separation of bound from free
antigen is generally done by a modification of the charcoal method of
Herbert et al. (1965), or by the antibody-capture technique of Poulsen
(1971). Radioimmunoassay procedures for A II were developed before those
for A I because of the earlier availability of the octapeptide as an
antigen. The A II assays are sensitive enough to measure circulating
levels of A II in normal man (Boyd et al., 1967; Catt et al., 1967; Gocke
et al., 1968; Goodfriend et al., 1968; Page et al., 1969; Sundsfjord, 1970).
Oparil and Haber (1974) reported that the apparent discrepancies between
methods can be attributed to differences in sodium intake and posture of
the subjects and a variability in extraction techniques. According to
Dietrich (1967) and Haber et al. (1969) levels of A II correlate well with
renin activity.
The use of the A II assay to determine renin activity has been less
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successful. When an assay for A II is used to measure renin activity, in
vitro conversion is necessary. Conditions favorable for the action of
plasma converting enzyme also favor angiotensinase action causing simul
taneous generation and destruction of A II (Oparil and Haber, 1974). Use
of a specific anti- A II antibody eliminates the conversion step and
permits a more direct accurate measurement of renin activity (Haber et al.,
1969; Boyd et al., 1969; Hollemans et al., 1969; Lehfeldt and Hutchens,
1971; Cohen et al., 1971). The inhibitors of converting enzymes that are
added to the incubation mixture also inhibit angiotensinase activity,
ensuing improved recovery of the generated peptide.
All of the commonly used radioimmunoassay procedures for renin ac
tivity employ an initial incubation step in which endogenous renin and
substrate react to generate A I. The reaction is then stopped usually by
freezing. 125I labeled A I and specific anti- A I antibody are added at
a later time and allowed to equilibrate with the generated A I in a second
incubation step. Bound and free forms of 125I - A I are then separated by
conventional techniques and quantitated by gamma or scintillation counting.
The amount of A I present is determined by a standard curve, according to
the methods of Bernson and Yallow (1968). Oparil and Haber (1974) main
tained that there are three main areas in which variations in procedure
have been introduced: pH of the initial incubation, choice of enzyme in
hibitors, and duration of the initial incubation. Detailed evaluations
and comparisons of methods for measuring renin activity are currently
being carried out in a number of laboratories. It is hoped that the
standardization of renin and angiotensin preparations, incubation condi
tions for generating angiotensin, and units of expressing renin activity
will facilitate comparison of renin activity measurement from laboratory
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to laboratory (Oparil and Haber, 1974).
Variability in incubation conditions for generating angiotensin and
in angiotensin standards has made comparison between bioassay and radio
immunoassay of plasma renin activity difficult to interpret. In one
study comparing normal values obtained in a number of laboratories, values
for renin concentration obtained by radioimmunoassay in reference to an
international renin standard were lower than bioassay values (Haas and
Goldblatt, 1972). With the use of the same plasma extracts for assay,
A I concentration has been reported to be consistently lower by radio
immunoassay than by bioassay (Cohen et a!., 1971; Menard and Catt, 1972),
or comparable to bioassay values (Kotchen et al., 1973). Oparil and
Haber (1974) suggested that the resolution will require measurement of
angiotensin samples generated under identical conditions by both bioassay
and radioimmunoassay with the same angiotensin standard in both pro
cedures.
It is difficult to measure the concentration of circulating A I with
accuracy. In vitro reaction of renin with its substrate, particularly
prominent in plasma that contains large amounts of renin or has been
allowed to become warm, cause false elevation of A I levels in unincubated
samples. Some antisera react with plasma components other than A I and
give falsely high results with unincubated plasmas (Page et al., 1971).
Appropriate selection of antisera will provide for the elimination of
this problem, since not all antibodies manifest such nonspecific cross-




Male Sprague-Dawley and Wistar spontaneously hypertensive rats
(SHR's) used in this investigation were obtained from Charles River
Breeding Laboratories, New York, M. Y. Systolic blood pressures of
all animals were monitored using a Programmed Electro-Sphygmomanometer
(model PE-300). This instrument was connected to a desk model Physio-
graph recorder (model DMP-48), from which readings were made. Both
instruments were purchased from Marco Bio-Systems, Inc., (Houston,
Texas).
The following chemicals were purchased from Sigma Chemical Co.
(St. Louis, Mo.); 3-estradiol-3-benzoate, 5-hydroxy-DL-tryptophan,
neomycin sulfate, bacitracin, Tris (hydroxymethyl) aminomethane (Trizma
base), Tris (hydroxymethyl) aminomethane hydrochloride (Trizma HC1),
ethylenediamine tetraacetic acid (EDTA), diidopropylfuorophosphate (DFP)
and bovine serum albumin (BSA).
Materials used in the radioimmunoassay procedures for the measure
ment of angiotensin I (A I) and angiotensin II (A II) were purchased from
New England Nuclear Biomedical Assay Laboratories (Worcester, Mass.); A I
(5-L Isoleucine) [tyrosyl-125I], A II (5-L-valine)[tyrosyl-125I] amide,
A I antiserum, A II antiserum, maleate buffer concentrate, A I standards,




Radioimmunoassay grade charcoal and Dextran T-70 were purchased
from Schwartz/Mann (Orangeburg, New York). Synthetic human A I and II
were obtained from Beckman Bioproducts, (Palo Alto, Cal.). Sodium
pentabarbital (Nembutal, 60 mg/ml) used for anesthetization was purchased
from Mosher, Inc., (Atlanta, Ga.). All reagents and stock solutions were
prepared in distilled or deionized water.
Gamma emissions from radioactive (monoiodinated) A I and II samples
were counted in a Beckman Liquid Scintillation Counter (model LS-230,
Beckman Instruments, Inc., Atlanta, Ga.). Centrifugations were done in
a Lourdes refrigerated centrifuge.
Methods of Procedure
All animals were fed Purina rat chow and tap water ad libitum unless
specified otherwise. Approximately 125 rats (initial avg. wt. 210-250 g)
were divided into 2 groups of controls, 1 group of doubly nephrectomized
rats, 3 experimental (induced) hypertensive groups and 1 group of
spontaneously hypertensive rats.
Blood pressure measurement
Systolic blood pressures of all animals were monitored 0-24 hr
prior to any experimental procedure. The tail cuff blood pressure method
was used, wherein a pneumatic cuff was placed around the base of the tail,
A pneumatic bulb connected to a pulse transducer was then secured (taped)
over the caudal artery. In this system, the animals were enclosed in a
warming chamber in order to increase blood circulation which usually
resulted in good pulsatile waves in the caudal artery. At all times
during the monitoring of blood pressures, the animals were secured in
specially built rat restrainers in order to minimize movement. A
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systolic blood pressure above 150 mm Hg in unanesthetized rats was
regarded as hypertensive (O'Steen et al., 1969).
Surgical procedures
All procedures involving surgery were performed after anesthetiza
tion with sodium pentabarbital (Nembutal, 40 mg/kg, ip). Operations
were done under aseptic conditions. Surgery involved opening of the
peritoneal cavity by making a mid-line incision along the linea alba
(2.0 - 2.5 cm in length). These procedures involved either placing a
clip around the left renal artery and removal of the right kidney (1-
kidney Goldblatt), removal of the right kidney leaving the left kid
ney intact (1-kidney nephrectomized), or removal of both kidneys (2-
kidney nephrectomy). After surgery the abdominal cavity was closed by
suturing with size 0-4 silk Ethicon surgical suture. The outer incision
was then closed with metal wound clips.
Collection of blood samples
Blood samples were collected at 10,20 and 30-day intervals after
each rat was decapitated. The blood was allowed to flow into 200 ml
beakers that had been rinsed with a 0.3% sodium citrate solution and
placed in an ice water bath (0-4 C). The samples were then measured
and poured into 10 ml polypropylene centrifuge tubes containing sodium
citrate (final concentration, 0.3%). Subsequent to collection, the
samples were centrifuged at 1,500 rpm in a refrigerated centrifuge (0-4 C).
Plasma samples were then decanted and stored in 7 ml si 1 iconized vacu-
tainers at -20 C until assayed for A I and A II concentrations.
One kidney Goldblatt hypertensive model
Forty-five male Sprague-Dawley rats were weighed, anesthetized and
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the right kidney removed. The left renal artery at the site where it
joins the dorsal aorta was dissected out of its tissue bed and a clip
(0.20-0.25 mm, i. d.) placed around the exposed artery. The clip was
a modification of that used by Goldblatt et al. (1934) made from silver
wire. The internal diameter of the clip varied according to the body
weight of the animals. The 0.20 mm clip was used for rats weighing up
to 200 g (initial avg. wt.), and for those weighing above 200 g a 0.25
mm clip was used. Controls for this model were 21 rats that had the
right kidney removed and the left kidney intact. Nine experimental
and 7 control rats were sacrificed at each designated time interval.
Salt-induced hypertensive model
The right kidney of 27 rats for this model was removed with the
left kidney left intact. After a 3-day recovery period, all animals in
this group were given 1.5% saline to drink. Controls consisted of 21
rats that had the right kidney removed, but given tap water to drink.
Nine salt-loaded and 7 control rats were sacrificed at each 10, 20, and
30-day interval, and plasma samples collected.
Malignant hypertensive model
Fifteen rats were administered an intraperitoneal (ip) injection of
5-Hydroxy-DL-Tryptophan (50 mg/kg) dissolved in 0.9% saline and a subcutan
eous (sc) injection of S-estradiol-3-benzoate in sesame oil (40 yg/0.1 ml)
simultaneously. Controls for this group were given a sham injection of
0.9% saline (ip) and 0.1 ml sesame oil (sc). Injections were made on day
1, 7, 14, 21, 42 and 47 with all surviving animals being sacrificed on
day 50 and plasma samples collected. Blood pressures of experimental and
control animals were recorded at each time interval prior to injections
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and on the day the experiment was terminated.
Spontaneously hypertensive model
The spontaneously hypertensive Wistar rats were direct descendants
of the Wistar strain developed by Okamoto and Aoki (1963). Twelve of
these rats (224-333 g) were sacrificed and plasma samples collected
(approx. age, 28-38 wks.).
Radioimmunoassay of antiotensin I
The radioimmunoassay procedures used for the determination of A I
concentrations in all plasma samples were based on protocols published by
New England Nuclear Biomedical Assay Laboratories. The assay system is
an adaptation of the radioimmunoassay methods of Haber et al. (1965,1969)
and Goodfriend et al. (1968). The assay consisted of 0.1 ml aliquot each
of a generated, and an endogenous sample of plasma. These samples con
sisted of 1.0 ml of plasma, 2.0 ml of 0.2 M maleate buffer (pH 6.0), and
0.1 ml of an inhibitor of both the plasma converting enzyme and the angio-
tensinases. The inhibitory mixture contained 5.0 mM EDTA, 0.32 M 8-
hydroxyquinoline sulfate, 0.05 M DFP and 0.2% bactracin in distilled
water. After vortexing, 1.0 ml of each plasma sample was incubated in a
water bath at 37 C for 1 hr, the rest of the sample was left at 0-4 C in
an ice water bath. To 0.1 ml of each of these plasma samples were added:
rabbit A I antiserum in tris-acetate buffer (0.1 M, pH 7.4, 0.5 ml) and
125I tyrosyl labeled 5-L isoleucine A I (approx. 8 pg/0.1 ml, specific
activity 500-1000 yCi/mg, 5-6000 counts/min), 0.1 ml. The final volume
of all samples was 0.7 ml and each sample was assayed in duplicate at
0-4 C.
Endogenous A I plasma samples were kept at 0-4 C at all times during
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the assay, while samples of generated A I were incubated at 37 C for
1 hr. Generation of the 37 C samples were terminated by immersion of
the sample into an ice water bath at 0-4 C. After an 18-24 hr incubation
period of all samples at 0-4 C, free and bound A I were separated using
a dextran T-70 treated Norit A charcoal suspension (pH 7.4). A total
volume of 1.0 ml of the charcoal suspension was added to each plasma
sample and the antibody bound and free A I separated by centrifugation
for 20 min at 4 C (5,000 rpm). The term endogenous refers to the actual
amount of A I in a plasma sample, while the term generated refers to the
amount of A I measured after incubation in a water bath at 37 C for a
period of 1 hr. All samples were assayed in 3.0 ml polystyrene test
tubes (silicone treated).
After charcoal filtration of free from antibody bound A I, gamma
emmissions of the supernatant were counted in a well type liquid scin
tillation counter. The process involved the use of 10.0 ml of Raiflour
in 15 ml scintillation vials into which the plasma samples were added.
Standards consisted of 0.1, 0.25, 0.5, 1.0, 2.5, and 5.0 ng/ml of
lyophilized synthetic human A I (0.1 ml aliquots). Standards were assayed
in the same manner as endogenous and generated plasma samples.
Procedures for calculating the values for each set of duplicate
standards and the unknown A I concentrations of 37 and 4 C plasma samples
were those suggested in the protocols for radioimmunoassay of A I published
by New England Nuclear Biomedical Assay Laboratories. The net counts per




% Bound = X 100
average net total counts
Using semi logarithmic graph paper, the percent bound for each standard
was then plotted against the amount of A I, as ng of A I added in the
0.1 ml standard solutions. The percent bound for the zero standard was
about 50-60%. Determination of the amount of A I in ng for each plasma
aliquot assayed was by interpolation from the standard curve. This was
done by converting the ng of A I for both 4 and 37 C samples into
ng/ml/hr by multiplying by 30 ("^VJ m1 = 3°)- plasma renin activity
was expressed as ng/ml/hr, calculated by subtracting the 4 C value from
the 37 C value (plasma renin activity = ng/ml/hr 37 C - ng/ml/hr 4 C).
Radioimmunoassa.y of angiotensin II
A modification of the antibody capture technique for A II proposed
by Poulsen (1971) and assay procedures for A II developed in the Atlanta
University laboratory were used for the determination of all plasma A II
concentrations. A II standards (0.0025-2.0 ng per 0.1 ml) were made with
synthetic human Asp1, Val5, A II (lyophilized) dissolved in 0.1 M tris-
acetate buffer with 0.2% BSA and 0.1% sodium azide (pH 7.4).
The assay was performed in disposable 3.0 ml capacity polystyrene
test tubes. All standards, and 4 and 37 C plasma samples were assayed
in duplicate. The assay consisted of 1.0 ml of each plasma sample, 0.1
ml of 3 M tris-HCl (10 vol percent, pH 7.3) and 0.03 ml of neomycin sul-
fate (3 vol percent, 60 ng/ml) dissolved in 0.2 M tris-HCl, pH 7.5. After
vortexing , 0.1 ml aliquots of each plasma sample was added to 0.1 ml of
rabbit A II antiserum. Two tubes of each sample containing this mixture
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were then incubated in a water bath at 37 C for 6 hr, while 2 tubes each
were left at 0-4 C in an ice water bath according to the method of Poulsen
(1971). Subsequent to the 37 C incubation period, an essential dilution
was performed by the addition of 0.1 ml of A II (5-L-Valine)(tyrosyl-125I)
amide (approx. 4 pg/0.1 ml, specific activity 1000-1500 yCi/mg, 9-10,000
counts/min) and 0.7 ml of 0.1 M tris-acetate buffer (pH 7.4) to each 4 and
37 C tube (see table I for A II assay protocol). The final volume of all
tubes was 1.0 ml. All samples were then incubated at 0-4 C for 18-24 hr.
After the incubation period, free A II was separated from the bound A II
using 1.0 ml of a 4% Norit A charcoal and 0.25% dextran T-70 suspension,
with subsequent liquid A I.
To determine the concentration of A II in ng, each plasma aliquot
assayed was interpolated from the standard curve after liquid scintillation
counting. The curve was obtained from A II standards (.0025-2.0 ng per
0.1 ml) assayed in duplicate simultaneously with plasma samples (Table 1).
The average net counts/min for all samples, total counts of controls and
standards were obtained by subtracting from each the average blank counts/
min. Percent bound was determined as in the radioimmunoassay for A I.
The ng of A II captured by the antibody for both 4 and 37 C samples
were converted to ng/ml/6 hr by multiplying by 11.3 ( * o.i'mi = 11-3)-
Converting enzyme activity was expressed as ng/ml/6 hr of captured A II.
This activity was obtained by subtracting the 4 C value from the 37 C
value.
Table 1. Radioimmunoassay protocol for angiotensin II (A II) determinations.





































All concentrations are in ml.
Std. = Standard
Ab. = Antibody (antiserum)
CHAPTER IV
RESULTS
All data in the tables and figures are mean values with standard
deviations (SD) of the mean. Statistical analyses were done according
to the student t-test. The null hypothesis was rejected at the 0.05 (5%)
level of probability. Computation of all data was performed at the
Atlanta University Center Computation Facility.
Blood pressure measurements
The production of persistent hypertension in laboratory animals has
provided methods for the investigation of various aspects of the renin-
angiotensin system. Mean systolic blood pressures of 3 models of
experimentally induced hypertensive rats produced for this purpose are
presented in Figs. 1 and 2, and Tables 2, 3, and 4. In 3 groups of rats
representing the one-kidney Goldblatt (1-K-G) model, terminal mean ele
vated blood pressures of 128.9, 141.8 and 169.3 mm Hg, respectively, were
attained at the end of 10, 20, and 30-day periods (Fig. 2, Table 2).
Figure 2 and Table 3 show that terminal mean blood pressures of 127.6,
123.0 and 135.4 mm Hg, respectively, were observed in 3 groups of rats
that were given 1.5% saline as drinking water for the same time periods
after removal of the right kidney (salt-induced hypertensive model).
Three groups of controls for both the salt-induced and 1-K-G models had
terminal mean blood pressures of 108.6, 110.9 and 106.2 mm Hg at the end
of the experimental periods. The experimental results show an elevation
of blood pressure to approximately 164 mm Hg in the malignant hypertensive


















































































Table 2. Statistical data comparing one kidney Goldblatt (1-K-G) model to their controls, and values






































































































































































B. P. = Blood Pressure
PRA = Plasma renin activity.
PCEA = Plasma converting enzyme activity.
± = Standard deviation of the mean.
* = P < 0.05 (significant value).
All values represent the mean for the number (N) of rats assayed at each timed interval.
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Table 3. Statistical data comparing salt-induced model to their controls, and values from 36 hr two






































































































































































B. P. = Blood pressure.
PRA = Plasma renin activity.
PCEA = Plasma converting enzyme activity.
+ = Standard deviation of the mean.
* = P < 0.05 (significant value).
All values represent the mean for the number (N) of rats assayed at each timed interval.
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Table 4. Statistical data comparing 5-hydroxy-tryptophan (5-HTP) model to their controls, and values






























































































B.P. = Blood pressure.
PRA = Plasma renin activity.
PCEA = Plasma converting enzyme activity.
f = Standard deviation of the mean.
All values represent the mean of the number (N) of rats assayed at each timed interval.
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controls for this group had a maximum mean blood pressure of 120.8 mm
Hg (Fig. 1 and Table 4).
Terminal blood pressures for the 36 hr 2-kidney nephrectomized
(2-K-N) rats were not measured. After nephrectomy, pulsations in the
caudal artery only showed heartbeats per min, which could not be converted
to blood pressure measurements. However, blood pressures of totally
nephrectomized rats can be measured by tail plethysmography, but not by
the tail cuff method used in our laboratory. When blood pressures were
measured in these rats prior to removal of both kidneys, a mean blood
pressure of 94.4 mm Hg was observed.
Mean blood pressure for the group of 13 SHR's used in this investiga
tion was 180 mm Hg (Fig. 1). The terminal mean weight of all rats used
for experimental purposes are presented in Tables 2, 3, and 4.
Validity of radioimmunoassay for determination of A I and A II concentrations
The following observations show the sensitivity or ability of the radio
immunoassay procedures used in this study to detect very low and high con
centrations of A I and A II in plasma. All concentrations derived from
such analysis of plasma samples are expressed as a mean value of the total
number of animals in each experimental group. Table 4 and Fig. 3 show the
resulting data computed after radioimmunoassay determination of the generated
and endogenous concentrations of A II in the plasma of 5 rats that had been
deprived of their source of renin (2-K-N) for 36 hr. These data, referred
to as plasma converting enzyme activity (PCEA), are derived from the gener
ated concentrations of A II minus the endogenous concentrations. The re
sults reveal a PCEA of only 0.06 ng/ml/6 hr for the 2-K-N plasma. The
generated A II (Fig. 4) and the endogenous A II (Fig. 5) plasma concentra
































































Fig. 10. Generated A II concentrations of 10, 20, and 30-day
kidney Goldblatt (1-K-G) and salt-induced experimental
plasma samples, compared to their controls. Vertical
bars represent the standard deviation (±) of the mean.
controls
1111 ll 1-K-G experimental
salt-induced experimentals
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value of 0.06 ng/ml/6 hr in the plasma samples of both the 10 and 20 day
salt-induced hypertensive rats, to 0.18 ng/ml/6 hr in the 30-day experi-
mentals (Fig. 9, Table 3). The values cited here show an increase of
200% in PCEA, but when compared to values of the controls and 1-K-G hyper
tensive rats, they become almost insignificant in the 10 and 20-day plasma
samples (Table 3). Controls for this experimental model were the same
animals used for the 1-K-G rats.
Similar activities for the malignant hypertensive model (5-HTP induced)
are illustrated in Fig. 3 and Table 4. These results show a decrease in
PCEA from 0.37 ng/ml/6 hr in the plasma of the controls to 0.16 ng/ml/6 hr
in that of the 5-HTP experimentals. These values represent a decrease in
PCEA of 131.2% in the 5-HTP experimentals when compared to the 5-HTP con
trol animals.
Generated and endogenous A II plasma concentrations
The values obtained by radioimmunoassay determinations of A II
concentrations in the experimental plasma samples after (generated A II)
and before (endogenous A II) 37 C incubation for 1 hr are illustrated in
Figs. 10 and 11, and in Tables 2, 3 and 4. Figures 10 and 11 demonstrate
that the plasma of the control animals representing both the 1-K-G and
the salt-induced hypertensive models show a decrease in both generated and
endogenous A II concentrations from 10 to 30 days. These values show a
100% decrease, or from 1.86 ng/ml at 10 days to 0.93 ng/ml at 30 days. A
93% decrease in endogenous A II concentration was observed during the same
time period. The latter values were from 1.18 to 0.61 ng/ml. In contrast,
there was an increase in concentrations in the 1-K-G experimental plasma




































































Fig. 9. Plasma converting enzyme activity (PCEA) of 10, 20, and
30-day one kidney Goldblatt (1-K-G) and salt-induced
experimental plasma samples, compared to their controls.
PCEA is expressed as a function of generated and endo
genous A II ocncentrations. Vertical bars represent the









































Fig. 8. Endogenous A I concentrations of experimental plasma
samples, compared to their controls, 36 hr two kidney
nephrectomized (2-K-N) and spontaneously hypertensive
rats (SHR's). Vertical bars represent the standard
deviation (±) of the mean.
A. [I I MB 36 hr 2-K-N




















































































Fig. 7. Generated A I concentrations of experimental plasma samples,
compared to their controls, 36 hr two kidney nephrectomized
(2-K-N) and spontaneously hypertensive rats (SHR's). Vertical
bars represent the standard deviation (±) of the mean.
A. f I Ml 36 hr 2-K-N
B. I 1 5-HTP controls
5-HTP experimentals





























































Fig. 6. Plasma renin activity (PRA) of control and experimental
plasma samples, expressed as a function of generated and
endogenous A I concentrations. Vertical bars represent













In contrast, the same type of data compiled from radioimmunoassay
determinations made simultaneously on plasma samples from a group of
13 SHR's reveal a PCEA of 0.48 ng/ml/6 hr (Fig. 3). The generated A II
plasma concentration in this group of rats was 1.20 ng/ml (Fig. 4), while
the endogenous A II was 0.71 ng/ml (Fig. 5). As is evident, the PCEA
of this group represents an increase of approximately 700% above that for
the 2-K-N rats.
Plasma renin activity (PRA) in the same plasma samples from the
2-K-N rats derived by similar computations of A I concentrations was
0.45 ng/ml/hr (Fig. 6). The generated A I concentration was 3.98 ng/ml
(Fig. 7), while the endogenous A I was measured at 3.52 ng/ml (Fig. 8).
PRA in the SHR plasma was 27.08 ng/ml/hr. These data demonstrate
that the PRA in the plasma of the SHR's was about 60 times greater than
that in the 2-K-N plasma samples. At the same time it was observed that
the concentration of generated A I in the SHR plasma sample was 34.39
ng/ml, compared to an endogenous concentration of 7.64 ng/ml.
Plasma converting enzyme activities in the experimental hypertensive models
The results referred to as PCEA were observed after radioimmunoassay
determinations of A II concentrations in the plasma of the 3 experimental
hypertensive models. The data obtained using modifications of the method
of Poulsen (1971) are presented in Fig. 9 and Tables 2, 3, and 4. Fig. 9
and Table 2 show a 64.4% increase in PCEA in the 1-K-G rats from 10 to 30
days. In contrast, when these results are compared with the controls it
can be seen that there is a decrease in PCEA of approximately 119% during
the same time periods.








































Fig. 5. Endogenous A II concentrations of experimental plasma samples,
compared to their controls, 36 hr two kidney nephrectomized
(2-K-N) and spontaneously hypertensive rats (SHR's). Vertical
bars represent the standard deviation (±) of the mean.
A. riMMI 36 hr 2-K-N
B. I 1 5-HTP controls
5-HTP experimental




































































































Fig. 4. Generated A II concentrations of experimental plasma samples,
compared to their controls, 36 hr two kidney nephrectomized
(2-K-N) and spontaneously hypertensive rats (SHR's). Vertical
bars represent the standard deviation (±) of the mean.






































































Fig. 11. Endogenous A II concentrations of 10, 20, and 30-day
one kidney Goldblatt (1-K-G) and salt-induced
experimental plasma samples, compared to their controls.




















































respectively, in generated and endogenous A II.
Plasma from the salt-induced rats also show increases in both
concentrations. For the generated sample the increase was 42.1% (from
0.38 to 0.54 ng/ml). An increase of only 11.1% was noted in the endo
genous A II samples from 10 to 30 days.
The 5-HTP plasma samples (figs. 7 and 8, and Table 4) show a de
crease in generated and endogenous A II when compared to the control.
The decrease in the generated sample was 79.5%, or from 0.79 ng/ml in
the controls to 0.44 ng/ml in the 5-HTP experimentals. The endogenous
A II plasma samples show a 50% decrease, or from 0.42 ng/ml in the con
trols to 0.28 ng/ml in the experimentals.
In the 36 hr 2-K-N plasma (Figs. 7 and 8, and Table 4) the concen
tration of generated A II was 0.56 ng/ml, while the endogenous concentra
tion was 0.49 ng/ml. These values reveal a difference of only 0.06 ng/ml
between the two concentrations. In contrast, the plasma of the SHR's show
a generated concentration of 1.20 ng/ml compared to an endogenous concen
tration of 0.71 ng/ml. The latter values represent a difference of 0.49
ng/ml.
Plasma renin activity
The experimental results illustrated in Fig. 12 show that the computed
PRA (generated minus endogenous concentrations of A I) in the 1-K-G experi
mental rats increases approximately 40.7% or from 39.98 ng/ml/hr at 10
days, to 46.40 ng/ml/hr at the end of the 30-day experimental period. In
comparison there was a 32.3% decrease in PRA in the control animals. The
PRA values for the 10 and 30-day controls were 35.69 and 26.98 ng/ml/hr,
respectively.
Fig. 12. Plasma renin activity (PRA) of 10, 20, and 30-day
one kidney Goldblatt (1-K-G) and salt-induced
experimental plasma samples, compared to their
controls. PRA is expressed as a function of generated
and endogenous A I concentrations. Vertical bars













































Very little PRA was detected in the plasma samples of the salt-
induced hypertensive rats (Fig. 12). PRA in the 10, 20, and 30-day
groups were 2.38, 1.51 and 2.26 ng/ml/hr in the order designated.
These data show significant decreases in PRA in this model when compared
to the controls and 1-K-G rats. PRA in the 5-HTP rats (Fig. 6) show a
decrease from 30.65 ng/ml/hr in the controls to 15.33 ng/ml/hr in the
experimentals. These values represent a 100% decrease in PRA for the
5-HTP induced hypertensive rats. Data pertaining to PRA in the 36 hr
2-K-N and SHR's have been reported in the results pertaining to the
validity of the radioimmunoassay for the determination of A I and A II
(Fig. 6 and Table 4).
Generated and endogenous A I concentrations
Figure 13 and Tables 2 and 3 show the computed data for the generated
concentrations of A I determined by radioimmunoassay. These results show
the differences between the control samples and that of 1-K-G and salt-
induced experimental collected at 10, 20 and 30 days. It is evident that
there is a 72.8% decrease in generated A I, or from 57.77 ng/ml at 10 days
to 33.42 ng/ml at 30 days in the control plasma samples. When compared to
the data for the 1-K-G samples, the concentrations increase by 52.3%, or
from 39.22 to 59.74 ng/ml during the same time periods.
From the salt-induced rats the generated A I values in the 10, 20 and
30-day plasma samples were 8.30, 5.27 and 6.68 ng/ml, respectively. These
values show no significant differences at either time period. The data
compiled for the 5-HTP samples reveal a 61% decrease in generated A I when
compared to the controls. The measured concentrations were 49.08 ng/ml
Fig. 13. Generated A I concentrations of 10, 20, and 30-day one
kidney Goldblatt (1-K-G) and salt-induced experimental
plasma samples, compared to their controls. Vertical


































in the control samples and 30.47 ng/ml in the 5-HTP experimentals.
Endogenous A I concentrations decreased 243% in the control
samples, but showed a 113.7% increase in the 1-K-G samples (Fig. 14
and Table 2). The concentration in the controls plasma was 22.07 ng/ml
at 10 days and 6.44 ng/ml at 30 days. Values for the 1-K-G plasma were
6.24 and 13.34 ng/ml at the same time periods. Concentrations of endo
genous A I in the plasma of the salt-induced animals were 5.92, 3.76,
and 4.42 ng/ml at the end of the 10, 20, and 30-day time periods. These
concentrations are not significantly different.
Fig. 14. Endogenous A I concentrations of 10, 20, and 30-day
one kidney Goldblatt (1-K-G) and salt-induced
experimental plasma samples, compared to their controls,























































The recent flurry of interest in the converting enzyme was probably
stimulated by two factors: the availability of a synthetic A I and the
discovery that in the dog in vivo,conversion of circulating A I to A II
takes place in the lungs (Ng and Vane, 1967, 1968) rather than in the
blood. Since then, considerable controversy has developed over the de
gree of conversion of A I to A II, not only in the lungs, but in the
plasma and other vascular beds.
These observations and the production of persistent hypertension in
laboratory animals by experimental procedures, have made it possible to
elucidate these and various other parameters of the renin dependent angio-
tensin system. Until recently, it had been assumed that all forms of
hypertension could be explained by the same mechanism, and various inves
tigators have used different animal models for the study of the effects of
renin on blood pressure. However, observations of the actions of the
angiotensins have led to the study of enzymes involved in the metabolism
of the liberated peptides, including the A I converting enzymes.
The precise identification of the form of angiotensin recovered from
in vitro incubation for plasma renin activity (PRA) determinations (A I,
A II or a mixture) has become increasingly important due to chemical
means for quantitation such as radioimmunoassay. Therefore, the possibility
to discriminate A I and A II quantitatively in mixtures by such methods
seemingly would provide means for a quantitative assessment of angioten
sin plasma converting enzyme activity (PCEA). Thus, it became questionable
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in our laboratory as to whether or not quantitative measurements of A I
simultaneously with A II could be determined. Consequently, measurement
of the ratio of A I to A II in plasma recovered as the 37 C incubation
product by radioimmunoassay was used to examine PCEA.
The simplified radioimmunoassay method of Poulsen (1971) was used for
studying PCEA. These procedures consisted of the capture of A II by use
of an excess of A II antibodies with subsequent PCEA determinations.
Methods previously available for measuring the activity of the converting
enzyme have been the bioassay methods of Helmer (1957) using isolated
strips of rabbit aorta, and of Bumpus et al. (1961) using isolated rat
uterus, Huggins and Thampi's (1968) chromatographic separation, and
Boucher et al. (1970) cation exchange adsorption technique. Many investi
gators have used these and other similar methods to study CEA, among them
being Anderson (1967), Barrett and Sambhi (1969), and more recently Fitz
et al. (1971). Only a few studies involving use of radioimmunoassay for
CEA determinations have been reported. One such study in particular was
that of Hollemans et al. (1969), cited because of its similarity to that
used in this study, the difference was that in the latter study, a con
verting enzyme preparation from human lung was used for the identification
of the incubation product of renin with subsequent radioimmunoassays for
A I and A II.
The present study involved the use of plasma samples from experi
mentally induced hypertensive rats, in which simultaneous determinations
of A I and A II concentrations were made with subsequent computations of
PCEA. Validity of the radioimmunoassay procedures used were determined
by the sensitivity of the assay to detect very low concentrations of A I
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and A II in the plasma from rats that had their source of renin removed
36 hr prior to the collection of plasma samples. Plasma from 24 hr
totally nephrectomized rats is known to show very little PRA due to
removal of the kidneys which is the major source of plasma renin. Con
sequently, since the product of PRA is A I, which is also the substrate
of the converting enzyme, the assays used should detect little or no
A I or A II, and subsequently markedly reduced PCEA in the 36 hr 2-K-N
plasma. PRA in the plasma samples from the 2-K-N rats examined were
only 0.45 ng/ml/hr (± 0.25). These findings are in agreement with those
of Lever and Robertson (1964) who found that PRA is markedly reduced or
abolished within 24 hr of removal of both kidneys. In contrast to the
reduced PRA detected in the 36 hr 2-K-N rats, the plasma from the SHR's
that had both kidneys intact, showed a maximum PRA of 27.08 ng/ml/hr
(± 7.4) at pH 7.4, the known optimal pH for renin substrate reaction. It
would therefore be reasonable to expect the PCEA to be markedly reduced
in the 2-K-N plasma (0.06 ng/ml/6 hr), and increased in the SHR's (0.48
ng/ml/hr). These results are also confirmed by those of Menard and Catt
(1972). They observed that the specificity of a similar radioimmunoassay
system for renin activity failed to detect A I after incubation of 500 yl
of 24 hr nephrectomized rat plasma up to 6 hr at 37 C.
The acute rise in blood pressure observed at 30 days when a clip is
placed around one artery (one kidney made ischemic) and the other removed,
has been well established since its development by Goldblatt (1934).
Many investigators have consequently used the technique to study hyper
tensive phenomena, and it is commonly agreed that such rises in blood
pressure in some types of experimentally induced animals are accompanied
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by either increases or decreases in renin related activities.
The knowledge that all forms of induced hypertensive animals are not
supported by the same mechanism is therefore essential to understanding
the different results obtained as concentrations of A I and A II determined
in plasma samples. As these concentrations vary in the plasma of the
different models or types of experimental hypertensive animals, apparently
PRA, and subsequently PCEA, would also vary.
In the 1-K-G hypertensive rats, increases of 40.7 and 64.4%, respec
tively, in PRA and PCEA from 10 to 30 days were reported. There must be
some correlation between PRA, PCEA, and blood pressure in this model.
Prior to the operation, these rats had initial mean blood pressures of
100.4 mm Hg, with increases of from 128.9 (± 15.71) at 10 days to 169.3
(± 18.43) mm Hg at 30 days. All increases (PRA, PCEA and blood pressures)
were significant (P < 0.05) when compared to the control animals at the
30-day period, because all of the latter animals showed decreases in the
same parameters during the same time periods.
Blood pressures of 108.6, 110.9 and 106.2 mm Hg were reported as
being observed in the control animals during the experimental period.
These rats had only the right kidney removed, and as in the 1-K-G rats,
received tap water to drink. PRA decreased from 35.69 at 10 days to
26.98 ng/ml/hr at 30 days. This decrease in PRA was approximately 33.2%,
while at the same time a decrease of 64.4% in PCEA was reported for these
rats (0.68 to 0.31 ng/ml/6 hr).
The chronic etiology or mechanisms that are probably responsible for
the observed differences in blood pressure and all other parameters in
the 1-K-G and their controls will not be discussed here. It may be
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important though to re-emphasize at this time that the transitory changes
in these animals must be borne by phenomena relative to the renin
dependent angiotensin system. Blood pressures in the control animals
remained relatively stable, but there were significant decreases in all
parameters observed (PRA, PCEA, and A I and A II concentrations).
Prior to the development of radioimmunoassay in the late 1950's and
I9601s, investigations relative to experimental hypertension involved
use of bioassay procedures to determine the effects of renin, the con
verting enzyme and their products on various kinds of smooth or involun
tary muscle tissue. Since its development, the procedure has been used
mainly to determine A I and A II concentrations in plasma and other
tissues in conjunction with PRA, PRC and PRS (Gocke et al., 1968; Poulsen,
1969b). Consequently, use of radioimmunoassay relative to the converting
enzyme has dealt mainly with aspects of the development of methods for
measurement of its activities, kinetics, inhibition and the sites of
conversions of A I to A II. Therefore, the etiology of hypertension and
parameters relative to the increases or decreases in PCEA and A II concen
trations observed in the experimental models and their controls are
further discussed in light of PRA and A I concentrations.
In furthur reference to the data obtained from radioimmunoassay
determinations of the 1-K-G plasma, Lever and Robertson (1964) reported
that during the first month of hypertension produced by constricting one
renal artery and removing the opposite kidney, significantly higher renin
levels are found. This confirms the present findings, discussed earlier.
They are further substantiated by Carretero and Gross (1967) who observed
that in experimental renal hypertension, increased renin production is
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accompanied by an increased concentration of PRS. The present findings
also correspond to observations in human hypertension by Helmer and
Judson (1963) in which both renin and its substrate (angiotensinogen)
were found to be elevated. Leenen and de Jong (1970, 1971) reported a
40% increase in PRA in venous blood from rats as early as day 1 upon
application of a solid renal arterial clip. The increase was 40.7% at
30 days in the present study, but the plasma used was from a mixture of
both venous and arterial blood.
It might be suggested that excessive renin release after renal ar
tery constriction and removal of the opposite kidney served as the stimu
lus for the rise in blood pressure. This assumption is in agreement with
Romero et al. (1970, 1973), however, these investigators suggest that a
high renin level is not necessarily involved in the continued maintenance
of hypertension. They theorized that renin secretion is the result of a
rise in blood pressure after unilateral constriction due to a negative
sodium balance. Their investigation was done using sheep with unilateral
artery constriction, followed in four weeks by removal of the opposite
kidney. These investigators assumed that when the first renal artery is
constricted, there is a rise in blood pressure followed by a transient
excessive sodium loss from the contralateral kidney, and that this may be
a stimulus for renin release. Blair-West et al. (1968) have shown after
similar experiments that such events accompany rises in blood pressure
and may explain the transient increase in PRA when one artery is con
stricted in the sheep. In other experiments the latter investigators
showed that if the blood pressure rose so as not to create a negative so
dium balance or if the contralateral kidney had previously been removed
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no increase in PRA was seen when the renal artery was clamped.
The present findings do not support the latter contention because
opposing results were observed at 30 days when the left renal artery was
constricted. For at the same time that the left artery was constricted,
the right kidney was removed, and still, an increase was observed in
PRA, PCEA, and A I and A II concentrations. Since these rats had as the
sole functional kidney, one that had its renal artery constricted, it
appears that other underlying mechanisms must have been responsible for
the simultaneous increase in blood pressure, and the other renin dependent
phenomena. Evidently, the development of 1-K-G hypertension cannot be
explained simply by the action of one or more substances that may be
released or produced in response to different stimuli, but is rather the
result of multifunctional regulation. It appears that the constriction
was the underlying factor responsible for the increased activities observed
in this hypertensive model.
Opposing results observed in the controls for the 1-K-G model can
more readily be interpreted as being in accord with the negative salt
balance theory of Blair-West et al. (1968). These rats had only one
kidney removed with no arterial constriction on the remaining kidney, and
while such a transient increase in all activities existed at day 10,
there was a tremendous decrease in all activities by the 30th day.
Generated A I and A II in the control animals decreased by 72.8% and 100%,
respectively, at 30 days. The concentrations at 10 days, 57.55 (A I) and
and 1.86 ng/ml (A II), were approximately the same as those reported for
the 1-K-G at 30 days, which were 59.74 and 2.07 ng/ml. PRA and PCEA
values also paralleled each other at these respective time periods.
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Therefore, it is reasonable to assume that a negative salt balance
existed in the controls from the time of the removal of one kidney until
the 10th day. Although there was no increase in blood pressure because
of the loss of one kidney at the 10th day, a transitory decrease in all
other activities was reported. The mechanisms underlying these observa
tions may be due to homeostasis, wherein the remaining kidney was per
forming all functions previously performed by two, and thereby showed
increases in all renin-dependent angiotensin activities. By the 20th
and 30th day, wherein decreases in these activities were reported, it is
assumed that homeostasis had been attained and that there was uniform
physiological stability with the one remaining kidney. This reasoning
is supported by the clinical observation that an animal can maintain
physiological stability with only one kidney and not encounter hyperten
sive disorders.
Opposing results from that reported for the control rats have been
presented in those given 1.5% saline as drinking water. Like the controls,
these rats also had the right kidney removed. PCEA increased from a
significantly low value of 0.06 ng/ml/6 hr at day 10 and 20 to 0.18
ng/ml/6 hr in the 30-day plasma. While this represents an increase in
activity of approximately 200%, it is of importance to emphasize that
these values are wery low when compared to similar PCEA's in the controls
and other experimental models.
If PCEA of the 10-day salt induced rats is compared to the same acti
vities in the 10-day controls, a significant decrease of 1033.3% is seen.
The decrease is not as pronounced in the 30-day animals; therefore, it
must again be re-emphasized that there was a decrease in PCEA in the
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control rats from 10 to 30 days. Furthermore, it is reasonable to expect
that in 30 days, there would be some attempt by the one remaining kidney
to overcome the effects of the chronic salt ingestion.
PRA was also reported as being significantly decreased at each time
period, averaging only 2.05 ng/ml/hr for the 3 time intervals. At 10
days a decrease in PRA of approximately 140% was seen when these activi
ties of the salt fed rats were compared with similar activities in the
controls. Significantly lower concentrations of generated and endogenous
A I and A II were also reported as being found in the plasma of the salt
loaded rats.
Systolic blood pressure in these rats increased from approximately 88.9
mm Hg at the beginning of the experiment to 135.4 mm Hg at 30 days.
The 30-day mean blood pressure does not appear to represent a chronic
state of hypertension, since it has been reported in our laboratory that
150 mm Hg represents the hypertensive state. The highest blood pressure
observed among 7 rats in the 30-day group was 152 mm Hg. In one rat, the
blood pressure only reached 124 mm Hg by day 30. These are not unexpected
results, for Dahl and Schackow (1964) reported that blood pressure
responses to chronic salt feeding in rats may range from none to ful
minating hypertension and even rapid death. They also reported that the
hypertension may develop at different intervals after the onset of salt
feeding. Once hypertension has appeared, it rarely ever disappears if
salt feeding is continued. In our laboratory, blood pressures as high as
235 mm Hg have been observed in rats during chronic salt ingestion. Two
rats from a beginning number of 9 in the 30-day group died during the
course of this experiment.
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Chronic salt ingestion apparently suppresses renin release from
the renin secreting cells of the kidney, thereby cutting off the renin-
angiotensin system. Carretero and Gross (1967) found that a high sodium
diet in rats is followed by a pronounced reduction in the concentration
of renin in the kidney and in plasma. If at the same time these rats
are administered deoxycorticosterone acetate, renin may fall to levels
too low to be estimated or even disappear completely. Moreover, Brown
et al. (1964) reported that when sodium intake is restricted, the juxta-
glomerular cells increase in size and granularity and that the extractable
renin of the whole kidney is elevated. A diet rich in sodium produces
the reverse effects. These ovservations, therefore, substantiate our
findings of an approximate 140% decrease in PRA when these activities in
the 10-day salt induced rats were compared to the controls.
Osteen et al. (1967) reported that the administration of serotonin
(5-hydroxytamine), or its precursor, 5-hydroxytophan (5-HTP) to mature
male rats is followed by severe renal cortical necrosis. Large doses of
5-HTP which caused as much as a ten-fold increase in the tissue serotonin
of treated rats had previously been observed by Undenfriend et al. (1957).
The pharmacologic effect of the precursor is believed to be primarily due
to the serotonin formed therefrom (Freter et al., 1957). The effects of
5-HTP on renal cortical tissue resemble malignant hypertension or the
cancerous state, in which there is a rapid degeneration of cells of the
kidney cortex.
It was reported that a group of 13 rats was administered injections
of 5-HTP simultaneously with injections of the hormone estradiol benzoate.
Mean systolic blood pressure increased from 105.4 at the beginning of the
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experiment to 164 mm Hg after 6 such injections 50 days later. Control
rats for this group of experimental hypertensive animals that were given
sham injections of 0.9% saline and 0.1 ml of sesame oil were reported as
demonstrating no significant increase in blood pressure. PCEA was found to
be significantly decreased (131.2%) from that of the controls when the ex
periment was terminated and the plasma assayed. PRA also decreased by ap
proximately 100%. Generated and endogenous A I and A II concentrations were
also reported as being decreased from those observed in the control animals.
Serotonin apparently controls the blood supply in the afferent vascular
bed of the renal glomeruli, decreasing glomerular blood flow and filtration
rate, and presumably also reducing the tubular blood supply (0'steen et al.,
1969). It had previously been found that 5-HTP caused more severe renal
lesions than did 5-HT, which suggested that the former might have a direct
nephrotoxic effect.
Interestingly, the latter investigators have observed that estradiol
benzoate in dosages devoid of any detectable effects on kidney structure or
blood pressure enhances the effect of 5-HTP on both in either sex. Presum
ably, the hormone exerts its effect on blood pressure by augmenting the ef
fect of 5-HTP upon those portions of the kidney critical to the development
of high blood pressure. Large doses of estradiol chronically administered
are believed to have some nephrotoxic action. Since estrogen (estradiol
benzoate) is a naturally occurring hormone and 5-HTP is the precursor of
the naturally occurring hormone, 5-HT, it was of interest to determine
whether a combination of the two substances could be employed to cause
elevated blood pressure.
Previously, resulting data have been discussed in light of the
combined effects of the two hormones on the components of the renin-
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angiotensin system. Despite the considerable body of evidence
implicating disturbed kidney function in the etiology of certain forms
of hypertension, the association is by no means invariable. When renal
alterations and hypertsnsion coexist, it is not always possible to
establish the cause and effect relationship between them. Therefore,
there exists a possible relationship between them and renal enzymatic
functions. If such were the case, it is at least conceivable that in
certain clinical circumstances the components essential to some forms of
human hypertensive disease could arise as a result of disturbed endo
crine balance involving these specific hormones.
Of the various procedures for producing hypertension in animals, the
simplest and most instructive has perhaps proved to be the original method
of Goldblatt et al. (1934) using constriction of the renal artery. This me
thod has the great advantage that structural damage to the renal parenchy
ma can be avoided. Therefore, most of the original experiments investi
gating the renin-angiotensin system has been based on this technique.
Indirect evidence of increased adrenocortical activity of the kidney
after occlusion (constriction) of the renal artery has been obtained by
enzymatic (PRA and PCEA) studies in plasma. When hypertension is produced
by constricting one artery in the rat, there is apparently an increase in
renin release based upon observation of increased PRA which has been pre
sented herein. Activities of the renal enzyme (renin) ultimately lead to
increased or decreased activities of the converting enzyme in plasma.
The latter activities subsequently affect the concentrations of A II
determined by radioimmunoassay procedures.
Decreases in these activities have been observed after chronic salt
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ingestion. Similar effects have been obtained also after the administra
tion of the serotonin hormone precursor, 5-HTP in rats, which causes
proximal tubular necrosis and gross changes in the renal cortex (O'steen
et al., 1967). It seems reasonable, therefore, to conclude that the
adrenal cortex is in some way apparently affected by such stimuli to
increased or decreased activities.
While these observations provide evidence for a direct renal-adreno-
cortical interaction in experimental hypertension, the question still
remains whether this interaction actually causes the blood pressure to
rise. If it does, what are the mode of operation and the site or sites
of action in the cardiovascular system? The most obvious manner in which
adrenal corticoids might act is by water or sodium retention associated
with redistribution of tissue electrolytes, which in turn might modify
vascular resistance or reactivity. The evidence for such changes in
experimental hypertension is inconclusive.
The discovery of the renin-angiotensin system and the similarity
between its hemodynamic effects and those of arterial hypertension ap
peared to provide a satisfactory basis for excessive vasoconstriction by
A II. Increased renin production by the damaged kidney has been postu
lated as the cause of renal hypertension. Unfortunately, proof of this
attractive hypothesis is still lacking.
The relevance of these various observations in laboratory animals
to hypertension in man is not entirely a matter for speculation. The
common features of human hypertension due to unilateral stenosis of the
renal artery, and high blood pressure in the rat due to renal artery con
striction, provide a sufficiently close parallel for the latter to be
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accepted as one of the most dependable experimental models for studying
the pathogenesis of renal hypertension in man. Much less certain is
the application of animal studies to essential hypertension. In the late
stages of essential hypertension, it might be possible that a renal fac
tor is superadded when renal vascular lesions or necrosis develop. As
has been demonstrated here by the use of 5-HTP, there is experimental
support for this. Further evidence has been provided by the demonstration
of increased secretion of aldosterone in malignant hypertension by many
investigators. It is a fair presumption that a closer understanding of
the pathogenesis of arterial hypertension in man will only be achieved by




The ability to quantitate A I and A II in mixtures of the peptides
such as is found in plasma provides methods that can be used to examine
plasma converting enzyme activities (PCEA). Therefore, measurements of
the ratio of A I to A II recovered as the 37 C incubation product in
plasma by radioimmunoassay determinations has been used to investigate
this renin-angiotensin dependent phenomenon. The antibody capture tech
nique was used for the determination of A II concentrations in plasma
from 3 experimentally induced hypertensive models of male Sprague-Dawley
rats.
1-Kidney Goldblatt Model
1. As blood pressure increased in these rats that had the left
renal artery constricted and the right kidney removed, an increase in
plasma renin activity (PRA) was accompanied by an increase in PCEA.
Increases in these enzymatic activities, apparently caused by the ar
terial constriction, are assumed to be due to a negative sodium balance
(sodium depletion).
2. Arterial constriction of the only functional kidney resulted in
increased renal enzymatic activities. The concentration of A I produced
reflects the subsequent PCEA with A II liberation.
3. The control rats for this model revealed no increase in blood
pressure during the experimental period, but both PRA and PCEA were in
creased at 10 days. Significant decreases of 33.2% and 64.4% respectively
in these activities were observed 20 days later. These observations in
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the controls indicate that some animals with one functional kidney can
maintain homeostasis and thereby regulate blood pressure.
Salt Induced Hypertensive Model
4. Due to chronic salt ingestion PRA was significantly suppressed
in the plasma of the salt fed rats. Subsequently, as A I concentrations
decreased, PCEA also decreased. These rats were given 1.5% saline as
drinking water for 30 days after removal of the right kidney. Therefore,
it is assumed that salt feeding suppresses renin release from the renin
secreting cells of the kidney. This phenomenon results in cutting off
the renin-angiotensin system.
5-hydroxytryptophan Induced Model
5. Administration of the serotonin hormone precursor, 5-HTP,
simultaneously with the hormone estradiol benzoate resulted in reduced
PRA and PCEA in the plasma of the experimental rats when compared to
their controls.
6. Large doses of 5-HTP apparently had nephrotoxic effects on the
kidney due to the serotonin hormone formed therefrom. This hormone is
believed to cause rapid degeneration of kidney cortical cells which
resemble malignant hypertension. This condition apparently resulted in
reduced tubular blood supply, and subsequently decreased renal enzymatic
activities.
7. Estradiol benzoate, when given in moderate dosages, is believed
to have no detectable effects on kidney structure or blood pressure. It
is assumed therefore, to enhance the effects of 5-HTP. Presumably, this
hormone exerts its effects upon those portions of the kidney critical to
the development of hypertension.
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8. Mean systolic blood pressure increased significantly in rats
injected with 5-HTP and estradiol benzoate over that of the controls
that were given sham injections (ip) of 0.9% saline and 0.1 ml of
sesame oil (sc).
Validity of the Radioimmunoassay for the Determination
of A I and All Concentrations
9. Thirty-six hr 2-kidney nephrectomized (2-K-N) rat plasma showed
markedly reduced levels of PRA, with subsequent decreases in PCEA.
These findings are apparently due to the removal of the source of the
renal enzyme, renin.
10. Reduced PRA activities resulted in decreased concentrations of
A I, the substrate of the converting enzyme. Decreased PCEA consequently
resulted in a reduction of A II, the vasoconstrictor hormone of the
renin-angiotensin system.
11. PRA was 60 times greater in the plasma of the spontaneously
hypertensive rats (SHR), while PCEA increased by approximately 700% over
that found in the 2-K-N plasma.
12. Results observed 36 hr after total nephrectomy, and in plasma
from SHR's imply that the radioimmunoassay is a sensitive method and can
be employed in the determination of PCEA. Apparently PCEA is a better
index for studying experimental hypertension in laboratory animals than
PRA studies, since its action is the last step in the renin-angiotensin
system prior to the liberation of A II.
Radioimmunoassay of A II has been employed for the measurement of
PCEA in rats and may provide a sensitive method for the assay of con
verting enzyme parameters in human beings. Moreover, there is increasing
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evidence for the necessity of simultaneous measurement of PRA, PCEA
and A I and A II during clinical studies on the renin-angiotensin
system. The ability to perform such measurements in blood samples from
small animals such as the rat also provide a valuable advantage,
particularly during studies which require accurate evaluation of serial
changes in the individual components of the renin-angiotensin system.
Finally, since A II is a more potent vassopressor agent than A I,
measurements of A II generated in vitro may be underestimated when
measured against A I.
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